Ginkgo Bioworks (US:DNA) ZACKSยท2025-07-25 23:16Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 6.31% in its stock price, closing at $13.96, while the S&P 500 gained 0.4% [1] - Over the past month, the company's shares have increased by 55.05%, significantly outperforming the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61% [1] Earnings Projections - The upcoming earnings disclosure for Ginkgo Bioworks is projected to show an earnings per share (EPS) of -$1.44, which reflects a 55% increase from the same quarter last year [2] - Revenue is estimated to be $43 million, indicating a 23.5% decrease compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict an EPS of -$5.56 and revenue of $180 million, representing changes of +46.33% and -20.72% from the previous year, respectively [3] - Recent changes to analyst estimates for Ginkgo Bioworks are important as they indicate the evolving nature of near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Position - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record of outperformance, with 1 stocks returning an average of +25% annually since 1988 [5] - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 95, placing it in the top 39% of over 250 industries [6] - The strength of individual industry groups is measured by the Zacks Industry Rank, which is based on the average Zacks Rank of individual stocks, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]